DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Gene therapy may help cure sickle cell disease, study says
A gene therapy that could provide a permanent cure for sickle cell disease continues to show success through a third wave of patients, researchers report.
The therapy, LentiGlobin, restored normal blood function in 35 sickle cell patients who had the one-time procedure, according to clinical trial findings published Sunday in the New England Journal of Medicine.
The patients are all now producing stable amounts of normal red blood cells containing healthy hemoglobin, said lead researcher Dr. Julie Kanter, director of the University of Alabama at Birmingham’s Adult Sickle Cell Clinic.
In addition, they have not suffered the severe pain episodes that come with sickle cell disease, she said.
Related Content
-
education & researchThe FDA Encourages New Treatments for Sickle Cell DiseaseThe FDA continues to work with stakehold...
-
education & researchThe Participation of Cohabitants With Sickle Cell Disease in Health Care: A Bibliographic StudyThis paper aims to analyze the published...
-
news & eventsCalifornia’s Stem Cell Agency Invests in Stem Cell-Based Therapies Targeting Sickle Cell Disease and CancerThe California Institute for Regenerativ...
-
news & eventsLa Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
-
news & eventsLentiGlobin Shows Positive Effects in Severe Sickle Cell Disease Patients, Phase 1/2 Data ReportsBluebird bio presented new positive resu...
-
news & eventsNew Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial ShowsA new pre-transplant conditioning regime...
-
news & eventsBluebird Bio Presents Data From LentiGlobin Gene Therapy TrialBluebird Bio’s investigational gene th...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.